Deep Track Capital
Deep Track Capital reported 66 stocks worth $6.8B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are GH (7.5%), IMVT (5.3%) and GPCR (3.8%). Compared with Q1 2026, the fund opened new positions in ALNY, COAG and GHRS, added to GH, GPCR and MANE, trimmed IMVT, ORKA and ALMS and sold out of BBIO, GERN and ANIP.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  GH Guardant Health Inc | $509M | 7.5% | 3.4M | +55K (+2%) | 8 of 8 | |
| 2 |  IMVT Immunovant Inc | $360M | 5.3% | 9.3M | −2.2M (−19%) | 8 of 8 | |
| 3 |  GPCR Structure Therapeutics Inc | $254M | 3.8% | 4.7M | +460K (+11%) | 8 of 8 | |
| 4 |  PCVX Vaxcyte Inc | $250M | 3.7% | 4.3M | No change | 6 of 8 | |
| 5 |  ALNY Alnylam Pharmaceuticals Inc | $248M | 3.7% | 825K | New position | 1 of 8 | |
| 6 |  MANE Veradermics Inc | $246M | 3.6% | 2M | +1.5M (+300%) | 2 of 8 | |
| 7 |  TARS Tarsus Pharmaceuticals Inc | $231M | 3.4% | 3.7M | +67K (+2%) | 6 of 8 | |
| 8 | NUVALENT INC | $220M | 3.2% | 1.8M | +407K (+30%) | 2 of 8 | |
| 9 |  ALKS Alkermes PLC | $210M | 3.1% | 4M | +410K (+11%) | 4 of 8 | |
| 10 |  OCUL Ocular Therapeutix Inc | $193M | 2.9% | 19.7M | No change | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
APELLIS PHARMACEUTICALS INC | $182M | 4.5M |
CENTESSA PHARMACEUTICALS PLC | $125M | 3.2M |
 BBIO Bridgebio Pharma Inc | $62.5M | 841K |
TERNS PHARMACEUTICALS INC | $56.6M | 1.1M |
 GERN Geron Corp | $47.3M | 31.7M |
🔒 Free account: see all 14.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 GMAB Genmab A/s | Call | $82.4M | 3M | +3,000,000 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Deep Track Capital 13F FAQ
What does Deep Track Capital own?
Deep Track Capital reported 66 stocks worth $6.8B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are GH (7.5%), IMVT (5.3%) and GPCR (3.8%). The table above lists every position in the filing (the top 10 without an account).
What did Deep Track Capital buy and sell in Q2 2026?
Compared with Q1 2026: 18 new positions, 21 added to, 15 trimmed and 14 sold out. New positions include ALNY, COAG and GHRS. It sold all of BBIO, GERN and ANIP.
When will Deep Track Capital file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Deep Track Capital's portfolio worth?
The Q2 2026 filing reports $6.8B in US stocks ($6.9B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.